Clinical Trial

Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

Study acronym: RiTOX
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to investigate the safety of rituximab for management of immune-related adverse events in malignant melanoma patients. The main questions it aims to answer are: * Is rituximab safe for management of immune-related adverse events in malignant melanoma patients? * Does rituximab provide indications of clinical benefit in the management of immune-related adverse events compared with corticosteroid treatment alone? Participants will: * Receive a single dose of 100 mg rituximab IV * Have regular follow-up consultations for 6 months following rituximab infusion * Follow a simultaneous corticosteroid tapering plan
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-07-01.
Trial Details
NCT Number NCT07694414
Lead Sponsor Inge Marie Svane
Conditions Immune-Related Adverse Events
Enrollment 25 participants
Start Date 2026-08-01
Primary Completion 2028-08-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-22